

Volagidemab

Cat. No.:	HY-P99383
CAS No.:	1233956-13-2
Target:	GCGR
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D) ^{[1][2]} .	
In Vivo	Volagidemab (5 mg/kg, s.c.) suppresses type 1 diabetes phenotype in Alloxan-induced diabetic mice ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Alloxan-induced diabetic mice ^[2]
	Dosage:	5 mg/kg
	Administration:	Subcutaneous injection (s.c.)
	Result:	Reduced phosphorylated CREB protein and PEPCK protein expression to nondiabetic levels.

REFERENCES

- [1]. Pettus J, et al. Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial. *Nat Med.* 2022 Oct;28(10):2092-2099.
- [2]. Wang MY, et al. Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway. *Proc Natl Acad Sci U S A.* 2015 Feb 24;112(8):2503-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA